3D Medicines (HKSE:01244) Debt-to-Asset : 0.20 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Debt-to-Asset?

3D Medicines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$245.7 Mil. 3D Medicines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$63.2 Mil. 3D Medicines's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was HK$1,562.9 Mil. 3D Medicines's debt to asset for the quarter that ended in Dec. 2023 was 0.20.

3D Medicines Debt-to-Asset Historical Data

The historical data trend for 3D Medicines's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Debt-to-Asset Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.04

0.06

0.13

0.20

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial			0.06	-	0.13	0.20	0.20

Competitive Comparison of 3D Medicines's Debt-to-Asset

For the Biotechnology subindustry, 3D Medicines's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

3D Medicines's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Debt-to-Asset falls into.

3D Medicines Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

3D Medicines's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(245.662	+	63.249)	/	1562.881
	=	0.20

3D Medicines's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(245.662	+	63.249)	/	1562.881
	=	0.20

3D Medicines (HKSE:01244) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

3D Medicines Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines